Evidence map›Paper›PMID 31980117›Full record

ReviewEndocrinology and metabolism clinics of North America2020

Role of Glucagon in Automated Insulin Delivery.

Leah M Wilson, Peter G Jacobs, Jessica R Castle

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology and metabolism clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06082973 (Evaluation of Dual-hormone Artificial Pancreas With Closed-loop Glucose Control Versus Single-hormone With Carbohydrate Recommendations Under Unannounced Exercise and Meal Challenge in Adults With Type 1 Diabetes.), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06082973 nacompletednot on this mapstarted 2024, after this paper: background citation

Evaluation of Dual-hormone Artificial Pancreas With Closed-loop Glucose Control Versus Single-hormone With Carbohydrate Recommendations Under Unannounced Exercise and Meal Challenge in Adults With Type 1 Diabetes.

TypeinterventionalSponsorUniversitat Politècnica de ValènciaRan2024 to 2025Enrolled15ConditionsType 1 DiabetesArmsAutomated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control, Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Type 1 diabetes - What's new in prevention and therapeutic strategies?Pediatric endocrinology, diabetes, and metabolism · 2023
    Article
  3. Algorithms for Automated Insulin Delivery: An Overview.Journal of diabetes science and technology · 2022
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leah M WilsonDivision of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Harold Schnitzer Diabetes Health Center, 3181 Southwest Sam Jackson Park Road, L607, Portland, OR 97239-3098, USA. Electronic address: wilsolea@ohsu.edu.
Peter G JacobsDepartment of Biomedical Engineering, Oregon Health & Science University, Mail Code: CH13B, 3303 Southwest Bond Avenue, Portland, OR 97239, USA.
Jessica R CastleDivision of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Harold Schnitzer Diabetes Health Center, 3181 Southwest Sam Jackson Park Road, L607, Portland, OR 97239-3098, USA.
Oregon Health & Science University · US

Funding

Improving glucose control with advanced technology designed for high risk patients with type 1 diabetesR01DK120367 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI JACOBS, PETER G, WILSON, LEAH MEGAN · 2018 to 2021
$2.4M
NIDDK NIH HHS R01 DK120367
6 · The paper itself

Abstract

Treatment of type 1 diabetes with exogenous insulin often results in unpredictable daily glucose variability and hypoglycemia, which can be dangerous. Automated insulin delivery systems can improve glucose control while reducing burden for people with diabetes. One approach to improve treatment outcomes is to incorporate the counter-regulatory hormone glucagon into the automated delivery system to help prevent the hypoglycemia that can be induced by the slow pharmacodynamics of insulin action. This article explores the advantages and disadvantages of incorporating glucagon into dual-hormone automated hormone delivery systems.

Indexed as

Insulin Infusion SystemsAutomationDiabetes Mellitus, Type 1Drug Therapy, CombinationGlucagonGlycemic ControlHumansHypoglycemiaInsulinPancreas, ArtificialGlucagonInsulinDual-hormone artificial pancreasGlucagonHypoglycemiaIntranasal glucagonMinidose glucagonType 1 diabetes

Identifiers

PMID31980117
PMCPMC7398489
OpenAlexW2996015198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.